Overview
- Lilly and AtaiBeckley announced a definitive agreement on Thursday under which Lilly will pay $6.75 per share cash upfront, valuing the deal at about $2.8 billion with up to $2.50 per share in contingent value rights worth roughly $1 billion if milestones are met.
- AtaiBeckley’s lead candidate, BPL-003, is a synthetic 5‑MeO‑DMT intranasal therapy that has Breakthrough Therapy designation and is in Phase 3, while VLS-01, a DMT buccal film, completed Phase 2b dosing with topline results expected in Q4 2026.
- The deal was approved by both boards and is scheduled to close in the third quarter of 2026 subject to AtaiBeckley shareholder votes and customary regulatory clearances.
- AtaiBeckley shares jumped more than 30% after reports and the announcement, trading above Lilly’s offer price as investors assigned limited near-term value to the milestone payments.
- The transaction expands Lilly’s neuroscience pipeline and follows heavy M&A funded by strong GLP‑1 sales, but commercial value will hinge on multi-year clinical readouts, FDA approvals, DEA rescheduling decisions, and the practical rollout of clinic-based delivery models.